Optic Ischaemic Neuropathy in Incretin‐Based Therapy: A Comparative Analysis of Real‐World Safety Data
Authors' conclusion
Significant post-marketing safety signals for optic ischaemic neuropathy were identified for semaglutide, tirzepatide, and liraglutide. The absence of signals with other glucagon-like peptide-1 receptor agonists argues against a uniform class effect.
Study context
- Population
- FDA Adverse Event Reporting System reports from each drug's approval date through Q3 2025
- Comparison
- Six incretin-based therapies: signals for optic ischaemic neuropathy
- Outcome
- Optic ischaemic neuropathy (MedDRA term): reporting odds ratio (ROR) and proportional reporting ratio (PRR)
Methodological detailsFDA Adverse Event Reporting System, OpenVigil 2.1, primary suspect drug reports only, Evans' criteria
- FDA Adverse Event Reporting System
- OpenVigil 2.1
- Primary suspect drug reports only
- Evans' criteria
Main finding
As reported in the abstract
Optic ischaemic neuropathy reporting signal
| Group | Value | Reporting odds ratio (ROR) (95% CI) | Proportional reporting ratio (PRR) (95% CI) |
|---|---|---|---|
| Semaglutide | 355 events | 94.45 (83.02-107.45) | 93.77 (82.48-106.61) |
| Tirzepatide | 49 events | 2.94 (2.20-3.93) | 2.94 (2.20-3.93) |
| Liraglutide | 13 events | 4.58 (2.65-7.91) | 4.58 (2.65-7.91) |
Value
Semaglutide355 events
Tirzepatide49 events
Liraglutide13 events
Reporting odds ratio (ROR) (95% CI)
Semaglutide94.45 (83.02-107.45)
Tirzepatide2.94 (2.20-3.93)
Liraglutide4.58 (2.65-7.91)
Proportional reporting ratio (PRR) (95% CI)
Semaglutide93.77 (82.48-106.61)
Tirzepatide2.94 (2.20-3.93)
Liraglutide4.58 (2.65-7.91)
Further findings
| Outcome | Values |
|---|---|
| Characteristics of semaglutide-associated reportsValue = mean age | Semaglutide mean 59 years · disability documented 18% · hospitalization 11% |
Original publication
Optic Ischaemic Neuropathy in Incretin‐Based Therapy: A Comparative Analysis of Real‐World Safety Data. Diabetes Obes Metab. Published 8 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →